Abstract The purpose of this study was to evaluate whether antihypertensive medication use, including longterm use, is associated with increased breast cancer incidence in women. We studied 210,641 U.S. registered nurses participating in the Nurses' Health Study (NHS) and Nurses' Health Study II (NHS II). Information on antihypertensive medication use was collected on biennial questionnaires in both cohorts, and breast cancer cases were ascertained during this period. Multivariable-adjusted Cox proportional hazard models were used to estimate relative risks of invasive breast cancer over follow-up (1988follow-up ( -2012follow-up ( in NHS, 1989follow-up ( -2011 in NHS II) across categories of overall antihypertensive medication use and use of specific classes (diuretics, beta blockers, calcium channel blockers, and angiotensin-converting enzyme inhibitors). During followup, 10,012 cases of invasive breast cancer developed (6718 cases in NHS and 3294 in the NHS II). Overall, current use of any antihypertensive medication was not associated with breast cancer risk compared with past/never use in NHS (multivariable-adjusted relative risk = 1.00, 95 % CI = 0.95-1.06) or NHS II (multivariable-adjusted relative risk = 0.94, 95 % CI = 0.86-1.03). Furthermore, no specific class of antihypertensive medication was consistently associated with breast cancer risk. Results were similar when we considered hypertensive women only, and when we evaluated consistency and duration of medication use over time. Overall, antihypertensive medication use was largely unrelated to the risk of invasive breast cancer among women in the NHS cohorts.
Introduction
Hypertension is highly prevalent among adults, especially with advancing age; the lifetime risk of hypertension exceeds 80 % in the United States [1] . Consequently, antihypertensive medications are commonly prescribed, and help limit the risk of cardiovascular-related conditions, including stroke, coronary artery disease, and heart failure [2] . Breast cancer is the most prevalent malignancy and the second leading cause of cancer death among women in the United States [3] . Numerous studies have examined the association of antihypertensive medication use and incident breast cancer; some [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , but not all [16] [17] [18] [19] [20] [21] [22] , studies have reported no association, although previous studies have generally lacked information on long-term use of these medications, which may have contributed to null findings. Still, two recent studies that collected such information reported that long-term use of antihypertensive drugs might be associated with an increased risk of breast cancer [20, 22] . One of these studies identified an association with use of any antihypertensive medication (although little information was available on individual classes of medication) [20] , and the second study found an association between long-term use of calcium channel blockers among current users (although the study was retrospectively designed, with a very small number of longterm users) [22] . To investigate this association further, we utilized longitudinal data from the Nurses' Health Studies (which, together, include [200,000 women) to prospectively evaluate the association of antihypertensive medication use, including different classes of medication and long-term use, with incident breast cancer in women.
Methods

Study population
The Nurses' Health Study (NHS) was established in 1976, when 121,701 U.S. female nurses, aged 30-55 years, returned a mailed questionnaire about their health and lifestyle [23] . In 1989, the Nurses' Health Study II (NHS II) was initiated among a younger generation of 116,434 female nurses aged 25-42 years [24] . Women have updated their information biennially with mailed questionnaires, and follow-up is C90 % in each cohort. Voluntary return of the questionnaires is considered to imply informed consent, and the Institutional Review Board of Brigham and Women's Hospital (Boston, Massachusetts) has approved both studies.
Ascertainment of antihypertensive medication use
Antihypertensive medication use was ascertained on most cohort questionnaires beginning in 1988 in NHS and 1989 in NHS II. In NHS, women were queried about their use of beta blockers, diuretics, calcium channel blockers, and ''other'' antihypertensive medications in 1988 and 1994, and every two years thereafter; angiotensin-converting enzyme (ACE) inhibitor use was ascertained in 1988, 1996, and every two years thereafter in this cohort. In NHS II, there was more variability in the timing of these queries: ''any'' antihypertensive use and diuretic use were assessed in 1989, 1993, and every two years thereafter; beta blocker use was queried in 1989, 2001 , and every two years thereafter; and calcium channel blocker use and ACE inhibitor use were assessed in 2001 and every two years thereafter.
Ascertainment of incident breast cancer cases
Breast cancer cases were identified during the period of June 1, 1988 to June 1, 2012 in NHS and June 1, 1989 to June 1, 2011 in NHS II. Nurses who reported breast cancer on cohort questionnaires were asked for permission to review their medical records, which was used to confirm breast cancer diagnoses. When medical records were unavailable, breast cancer cases were defined as probable and included in the analysis if corroborated by phone interview or written confirmation from the participant. In some cases, breast cancer was reported during death follow-up, when family members, the postal service, or the National Death Index informed the study of a participant's death. The National Death Index was also reviewed after each questionnaire cycle to determine the status of women who were unresponsive to cohort questionnaires. In both cohorts, self-reported breast cancer was [98 % accurate compared to pathology reports [25, 26] ; thus, although pathology reports were pending for 8 % of cases in NHS and 12 % cases in NHS II, we based our analyses on the total cases because of this high accuracy.
Ascertainment of possible confounding variables
Covariate information was derived from participants' self reports on biennial questionnaires in both cohorts.
Population for analysis
In NHS, 103,551 women first provided information on antihypertensive medication use in 1988; in NHS II, antihypertensive medication use was assessed at baseline, in 1989, among all 116,343 participants. Of these, we excluded 2304 women with breast cancer diagnoses (2098 invasive cases and 206 in situ cases) prior to 1988 in NHS, and five women with such diagnoses (three invasive cases and two in situ cases) in NHS II. We also excluded women with a prior diagnosis of other cancers (except non-melanoma skin cancer) at baseline (n = 5637 in NHS and n = 1045 in NHS II). Finally, we removed 109 participants in NHS and 239 participants in NHS II because they did not report information on height-an important risk factor for breast cancer in women [27] . After these exclusions, 95,501 women in NHS and 115,140 women in NHS II constituted our baseline population.
Statistical analysis
Follow-up began with the initial report of antihypertensive medication use in our cohorts: 1988 in NHS and 1989 in NHS II. Because antihypertensive medications of interest were not assessed on every cohort questionnaire, we carried forward information that had been previously ascertained until the next questionnaire cycle that included new information for a particular medication. We used several approaches to examine the association between antihypertensive medication use and risk of invasive breast cancer in each of the NHS cohorts. First, we examined current use of any antihypertensive medication as well as individual classes of medication (diuretics, beta blockers, calcium channel blockers, and ACE inhibitors), updating this information biennially. Second, we restricted our analyses to women with a diagnosis of hypertension (n = 61,427 in NHS and n = 36,036 in NHS II) to address the possibility of confounding by indication, and eliminate hypertension as the primary reason for any observed associations. Third, we evaluated women according to consistency of antihypertensive medication use: consistent use, inconsistent use, and never use. Women were assigned to ''consistent use'' if they reported current antihypertensive medication use, either for the first time or after reporting such use on every questionnaire following their initial report of use. Women were assigned to ''inconsistent use'' if they reported no current antihypertensive medication use after previously reporting antihypertensive use. Women were assigned to ''never use'' if they reported no current use of antihypertensive medications after never reporting antihypertensive use previously. Finally, we extended our consistency analyses to incorporate duration of medication use among women with ''consistent use''. To calculate duration, we assumed two years of medication use every time a participant reported use of antihypertensive medications on a biennial questionnaire, and then added these years together.
In NHS II, the initial report of calcium channel blocker and ACE inhibitor use occurred in 2001; thus, for current use analyses, we imputed 2001 information for questionnaire cycles from 1989 through 1999 to maximize the number of breast cancer cases utilized in our analyses. (Results were very similar using this approach compared to beginning these analyses in 2001, with fewer breast cancer cases). Consistency and duration analyses were begun in 2001, when all classes of antihypertensive medications began to be consistently included on the cohort questionnaires.
We used Cox proportional hazards models to estimate age-and multivariable-adjusted relative risks (RR) of incident breast cancer, with 95 % confidence intervals (CI). We used age (in months) as the time scale in our models, and calculated person-time from the return date of the baseline questionnaire through the end of follow-up (June 1, 2012 in NHS and June 1, 2011 in NHS II), date of breast cancer diagnosis, date of death, or loss to follow-up, whichever occurred first. Statistical models were adjusted for the following potential confounding factors: body mass index, height, oral contraceptive use, menopausal status, age at menopause, postmenopausal hormone use, age at first birth and parity, age at menarche, family history of breast cancer, history of benign breast disease, alcohol intake, physical activity, smoking history, and shift work history. These covariates were determined at baseline and updated at each follow-up cycle; missing indicators were utilized to represent missing data in statistical models. We also considered possible confounding by aspirin use and mutual adjustment for each of the different antihypertensive medications, but neither approach changed our effect estimates; thus, these adjustments were not included in our final models.
In secondary analyses, we stratified our models according to estrogen-receptor (ER) status of breast tumors and aspirin use, testing for heterogeneity using the likelihood ratio test. All p values were two sided and considered statistically significant if p \ 0.05. We used SAS software, version 9 (SAS Institute, Cary, North Carolina, United States) for all statistical analyses.
Results
There were 10,012 cases of invasive breast cancer (6718 cases in NHS and 3294 in NHS II) that developed over follow-up. Table 1 describes age and age-adjusted characteristics of 179,021 women participating in the NHS cohorts at the midpoint of follow-up, according to current versus past/never use of antihypertensive medication. As Table 1 expected, the majority of women who reported current use of antihypertensive medication had a diagnosis of hypertension (88 % in NHS and 69 % in NHS II). Most characteristics were similar comparing current versus past/ never antihypertensive users, although current users of these medications tended to be older, with higher body mass index, lower physical activity levels, and less regular use of aspirin compared with past/never users. Moreover, we observed greater use of antihypertensive medications over time in both cohorts (data not shown).
In age-and multivariable-adjusted models, the risk of incident breast cancer was similar among current versus past/never antihypertensive users (multivariable-adjusted [MV] RR = 1.00, 95 % CI = 0.95-1.06 in NHS, and MV RR = 0.94, 95 % CI = 0.86-1.03 in NHS II) ( Table 2) . When examining specific classes of antihypertensive drugs, in age-adjusted models, current use of calcium channel blockers was related to a small increase in breast cancer risk in NHS (RR = 1.10, 95 % CI = 1.01-1.19), but not in NHS II (RR = 0.94, 95 % CI = 0.76-1.17). This association was attenuated after multivariable adjustment in NHS (MV RR = 1.07, 95 % CI = 0.99-1.17), and remained non-significant in NHS II (MV RR = 0.97, 95 % CI = 0.78-1.20). Current use of diuretics, beta blockers, and ACE inhibitors was not related to incident breast cancer in NHS in age-or multivariable-adjusted models. In NHS II, ACE inhibitor use was associated with lower risk of breast cancer in age-and multivariable-adjusted models (MV RR = 0.74, 95 % CI = 0.62-0.89, comparing current versus past/never users of ACE inhibitors), whereas use of diuretics and beta blockers was not related to breast cancer risk. Results were similar when we restricted our analyses to hypertensive women only (Table 3) .
In addition, consistent use of antihypertensive medications was not related to risk of developing breast cancer in either age-or multivariable-adjusted models; the multivariable-adjusted RR was 0.99 (95 % CI = 0.93-1.05) in NHS and 0.95 (95 % CI = 0.84-1.07) in NHS II ), height (inches), oral contraceptive use (never, ever), menopausal status (premenopausal, postmenopausal), age at menopause (\45, 45-49, 50-52, C53 years), postmenopausal hormone use (among postmenopausal women only: never, past, current), parity and age at first birth (nulliparous, 1-2 children and \25 years old, 1-2 children and 25-29 years old, 1-2 children and C30 years old, C3 children and \25 years old, C3 children and C25 years old), age at menarche (\12, 12, 13, C14 years old), family history of breast cancer (yes, no), history of benign breast disease (yes, no), alcohol intake (none, 1-7.49, 7.5-14.99, 15-29.9, C30 grams/day), physical activity level (quintiles of MET-hours/week), smoking status (never or past, current and \25 cigarettes/day, current and C25 cigarettes/day), and shift work history (none, 1-9, C10 years)
comparing consistent versus never users of antihypertensive medication (Table 4) . When we evaluated individual classes of antihypertensive medications, we found a small, borderline reduction in breast cancer risk among women who reported consistent versus never use of beta blockers in NHS only (MV RR = 0.93, 95 % CI = 0.86-1.00). Furthermore, in NHS II only, consistent users of ACE inhibitors had a lower risk of breast cancer compared to never users of these medications (MV RR = 0.76, 95 % CI = 0.60-0.96). All other associations between antihypertensive medications and breast cancer risk were nonsignificant in analyses that considered consistency of medication use. Similar results were apparent in analyses that divided consistent users of antihypertensive medications into categories according to duration (Table 5 ). There were no trends for duration of medication use across the various antihypertensive medications, except that longer, consistent use of ACE inhibitors was related to a decreased risk of breast cancer in NHS II (p trend = 0.01, MV RR = 0.57, 95 % CI = 0.35-0.94 comparing consistent users with C6 years of ACE inhibitor use vs. never use of these medications). Still, longer duration of ACE inhibitor use was not associated with breast cancer risk in NHS (p trend = 0.06, MV RR = 0.90, 95 % CI = 0.51-1.59 comparing C16 years of consistent use vs. none), where exposure data were reported consistently over a longer time period, and therefore longer durations could be evaluated.
Finally, in stratified analyses, we found few differences in the associations of antihypertensive medication use and incident breast cancer according to ER tumor status. Beta blocker use was related to a reduced risk of ER-tumors (MV RR = 0.77, 95 % CI = 0.62-0.96 comparing current vs. past/never users), but not ER? tumors (MV RR = 1.00, 95 % CI = 0.92-1.09 for the same comparison), in NHS (p heterogeneity = 0.02); however, there was no such difference in NHS II (p heterogeneity = 0.2) (see Online Resources 1 and 2). Calcium channel blocker ), height (inches), oral contraceptive use (never, ever), menopausal status (premenopausal, postmenopausal), age at menopause (\45, 45-49, 50-52, C53 years), postmenopausal hormone use (among postmenopausal women only: never, past, current), parity and age at first birth (nulliparous, 1-2 children and \25 years old, 1-2 children and 25-29 years old, 1-2 children and C30 years old, C3 children and \25 years old, C3 children and C25 years old), age at menarche (\12, 12, 13, C14 years old), family history of breast cancer (yes, no), history of benign breast disease (yes, no), alcohol intake (none, 1-7.49, 7.5-14.99, 15-29.9, C30 grams/day), physical activity level (quintiles of MET-hours/week), smoking status (never or past, current and \25 cigarettes/day, current and C25 cigarettes/day), and shift work history (none, 1-9, C10 years) , height (inches), oral contraceptive use (never, ever), menopausal status (premenopausal, postmenopausal), age at menopause (\45, 45-49, 50-52, C53 years), postmenopausal hormone use (among postmenopausal women only: never, past, current), parity and age at first birth (nulliparous, 1-2 children and\25 years old, 1-2 children and 25-29 years old, 1-2 children and C30 years old, C3 children and\25 years old, C3 children and C25 years old), age at menarche (\12, 12, 13, C14 years old), family history of breast cancer (yes, no), history of benign breast disease (yes, no), alcohol intake (none, 1-7.49, 7.5-14.99, 15-29.9, C30 grams/day), physical activity level (quintiles of MET-hours/week), smoking status (never or past, current and \25
cigarettes/day, current and C25 cigarettes/day), and shift work history (none, 1-9,
use was associated with a significantly increased risk of ER-tumors in NHS (MV RR = 1.36, 95 % CI = 1.09-1.70 for current vs. past/never users) and a nonsignificantly elevated risk of ER-tumors in NHS II (MV RR = 1.20, 95 % CI = 0.75-1.93 comparing current vs. past/never users), although p values for heterogeneity were not significant between tumor types. Moreover, analyses stratified by aspirin use were similar to our overall results (results not shown).
Discussion
Overall, we found that antihypertensive medication use was largely not associated with the risk of invasive breast cancer among women participating in the NHS cohorts, in accordance with a previous analysis in NHS, which included six years of follow-up [8] . Our results were generally similar across analyses of current antihypertensive medication use, hypertensive women only, and consistency and duration of medication use over two decades of followup. Thus, in contrast to two recent studies utilizing longterm data on antihypertensive medication use [20, 22] , and consistent with a recent study from the Swedish National Board of Health and Welfare [15] , our findings do not indicate that use of these medications generally, or calcium channel blockers specifically, is associated with an increased risk of developing breast cancer. Recent studies that reported long-term use of antihypertensive medication was related to an increased breast cancer risk utilized somewhat different study designs compared to our study. The first of these studies, conducted in a cohort of California teachers, was a prospective cohort study with 4151 incident cases of breast cancer occurring between 1995 and 2006 [20] . A baseline questionnaire was used to assess women's history of antihypertensive medication use, but updated information on medication use during follow-up was not incorporated into analyses of long-term medication use. The study reported an increase in the risk of breast cancer among women with a longer history of antihypertensive use compared with those with no history of use, but the point estimate was relatively small (RR = 1.18, 95 % CI = 1.04-1.34 comparing women with C10 years of antihypertensive medication use vs. none), and information on specific antihypertensive medications was limited to diuretic use; thus, interpretability of these results is somewhat limited.
A recent retrospective, case-control study among women in Seattle-Puget Sound provided more specific analyses related to different classes of antihypertensive medication in relation to breast cancer risk [22] . In that study, use of calcium channel blockers for C10 years among current users was associated with an increased breast cancer risk that was approximately 2.5 times greater compared to women who never used antihypertensive medications, although CI for these estimates were wide due to the small number of participants in the longest duration category (n = 12 controls, 27 ductal cases, and 31 lobular cases) (RR = 2.4, 95 % CI = 1.2-4.9 for invasive ductal cases, and RR = 2.6, 95 % CI = 1.3-5.3 for invasive lobular cases). Thus, this finding needs to be interpreted very cautiously, especially given the very small number of controls that comprise the reference group for both of these estimates.
In contrast, our current study found no overall association between calcium channel blocker use and breast cancer risk, including among current, long-term users, in analyses of C10,000 invasive breast cancer cases and C150,000 non-cases across the NHS cohorts (our longduration categories for ''consistent users'' are current, longterm users by definition). This result is consistent with recent findings from the Swedish National Board of Health and Welfare, which reported that five-year use of calcium channel blockers was not associated with breast cancer risk in a prospective case-control study (MV odds ratio = 1.1, 95 % CI = 0.9-1.3); however, data on longer-term medication use were not available in that study [15] . Although we found a small (10 %) increase in breast cancer risk among current users of calcium channel blockers in NHS, this association was borderline significant and not present in consistent, long-duration users in this cohort, or among women taking calcium channel blockers in NHS II. There was also some suggestion that current users of calcium channel blockers might have an elevated risk of ER-breast cancer in NHS, and perhaps in NHS II as well. However, there is no prior biologic reason to believe that calcium channel blockers would be associated with ER-tumors specifically; thus, this finding should be interpreted cautiously, and explored in future studies. Taken together, then, our findings do not support an overall association of calcium channel blocker use, including longterm use of these medications, with breast cancer risk in women.
Although there was no overall association between use of antihypertensive medications and breast cancer risk in our study, a potentially intriguing finding is that use of ACE inhibitors was related to a decreased risk of breast cancer among women participating in NHS II. This finding is similar to results in the Seattle-Puget Sound study, which identified a borderline significant risk reduction for ductal and lobular breast cancers among women using ACE inhibitors over long durations (RR of ductal breast cancer = 0.7, 95 % CI = 0.5-1.2, and RR of lobular breast cancer = 0.6, 95 % CI = 0.4-1.0, comparing C10 years of ACE inhibitor use vs. never using antihypertensive medications) [22] . However, there is limited biologic evidence to indicate a specific mechanism by which ACE inhibitors would reduce the risk of breast cancer in women, and no evidence that these medications reduce breast cancer survival according to a previous study in this cohort (RR = 0.89, 95 % CI = 0.60-1.32 comparing current vs. never/past users) [28] . Thus, the association that we observed should not be over-interpreted in our findings, although future studies should further investigate this association.
We also observed a modestly reduced risk of breast cancer incidence among consistent users of beta blockers in NHS, although it was small (i.e., a 9 % risk reduction) and not found in analyses that considered duration of medication use or in analyses of the NHS II cohort. In addition, beta blockers are known to decrease melatonin secretion in the body [29] , and lower melatonin levels have been associated with an increased risk of breast cancer in the NHS cohorts [30, 31] . Thus, we would have expected any observed association to indicate that consistent use of beta blockers elevated breast cancer risk-further suggesting that the association in NHS is likely due to chance.
Our study has several limitations. First, this is an observational study and therefore we cannot rule out the possibility of residual confounding due to unmeasured or poorly measured factors. We adjust our statistical models for a wide variety of health and lifestyle factors, including multiple risk factors for breast cancer, which produced relatively little change in our effect estimates compared with age-adjusted models. Thus, although we cannot definitively rule out residual confounding as an explanation for our findings, we have minimized this possibility by carefully considering many potential confounding factors. Second, use of antihypertensive medications was self-reported by women in the NHS cohorts, and therefore some random exposure misclassification may have occurred in our study. However, our nurse participants are likely to report their medication use accurately due to their high level of health-related knowledge, and previous validation studies in NHS indicate that the validity of self-reported hypertension and other health information is very high [32] . For questionnaire cycles without information on particular antihypertensive medications, we carried forward women's most recent report, and this assumption may have resulted in some misclassification of our exposure. However, such misclassification is less likely to have influenced our results given the similarity of our main findings to results based on the subgroup of women with hypertension, who are likely to have continued their use of antihypertensive medications. Finally, we only had information on broad classes of antihypertensive medications in our cohorts, and therefore we could not evaluate associations between specific subclasses (e.g., short-acting vs. long-acting, or dihydropyridine vs. non-dihydropyridine calcium channel blockers) and breast cancer incidence. However, results of the Seattle-Puget Sound Study do not suggest that associations differ across these subclasses; thus, we may have captured the most relevant information by asking women to report their use of antihypertensive medications in broad classes [22] .
In conclusion, we found that use of antihypertensive medications, including calcium channel blockers, was not related to breast cancer risk among women participating in the NHS cohorts. Our study evaluated current use and longer-term use of antihypertensive medications, and results were generally consistent across these analyses. Importantly, our study differs from several previous reports utilizing long-term drug information, which had suggested that antihypertensive medications, including calcium channel blockers, may increase the risk of breast cancer in women. Future studies are needed to confirm these findings.
